

## Medical Education

### Advanced therapies in severe asthma (GB-29013)

Dr David Jackson

---

---

#### Reference list

- Brusselle G, Maes T, Bracke K. Eosinophils in the Spotlight: Eosinophilic airway inflammation in nonallergic asthma. *Nat Med* 2013;19(8):977–979.
- Sweeney J et al. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry. *Thorax* 2016;71:339–346.
- National Institute for Health and Care Excellence (NICE). Benralizumab for treating severe eosinophilic asthma. Technology appraisal guidance (TA565). London: NICE, 2019.
- Nair P et al. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. *N Engl J Med* 2017;376:2448-58
- Bel EH et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. *N Engl J Med* 2014;371:1189-97
- Farne HA et al. Cochrane Database of Systematic Reviews 2017, Issue 9. Art. No.: CD010834. DOI: 10.1002/14651858.CD010834.pub3
- National Institute for Health and Care Excellence (NICE). Mepolizumab for treating severe eosinophilic asthma. Technology appraisal guidance (TA431). London: NICE, 2017.
- National Institute for Health and Care Excellence (NICE). Omalizumab for treating severe persistent allergic asthma. Technology appraisal guidance (TA278). London: NICE, 2013.
- National Institute for Health and Care Excellence (NICE). Reslizumab for treating severe eosinophilic asthma. Technology appraisal guidance (TA565). London: NICE, 2017.
- NHS England. PSS8 Severe Asthma Specialised Care Review PSS CQUIN Indicator. July 2019. Available from: <https://www.england.nhs.uk/publication/pss8-severe-asthma-flat-final-pss-cquin-indicator/>